Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RAPID-COVID

Financiado

Cerrado

Robust Automation and Point of Care IDentification of COVID

As of 30th March 2020, the COVID-19 outbreak had caused over 735,000 infections globally, claiming more than 35,000 lives. By the end of July 2020 these numbers have increased globally to more than 17 millions infections and more... ver más

30/04/2022

GeneFirst Ltd.

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

GENEFIRST LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-04-30

IMI2-2020-21-01: Development of therapeutics and dia...

I+D

Cerrada hace 4 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

GeneFirst Ltd.

1.01M€ | Lider

Primadiag

657.46K€ | Participante

ASSISTANCE PUBLIQUE HOPITAUX...

543.81K€ | Participante

APESCS

311.25K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IRIS-COV Market Release of a Portable Device for COVID 19 at the Poin... 3M€ Cerrado

PID2020-116728RB-I00 DESARROLLO DE BIOSENSORES DE ULTIMA GENERACION PARA EL DIAGN... 132K€ Cerrado

DECODE reDucing the health and Economic COst of Diagnostic uncErtai... 4M€ Cerrado

RAPP-ID Development of RApid Point of Care test Platforms for Infect... 16M€ Cerrado

PID2020-118904RB-C22 DESARROLLO DE TESTS RAPIDOS Y ULTRASENSIBLES PARA INFECCIONE... 74K€ Cerrado

Duración del proyecto: 20 meses Fecha Inicio: 2020-08-11
Fecha Fin: 2022-04-30

Líder del proyecto

GENEFIRST LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto As of 30th March 2020, the COVID-19 outbreak had caused over 735,000 infections globally, claiming more than 35,000 lives. By the end of July 2020 these numbers have increased globally to more than 17 millions infections and more than 660,000 lives have been lost due to the disease. Rapid and definitive diagnosis of the specific SARS-CoV-2 is essential, while identifying other common viral and bacterial pathogens is beneficial in the management of treatment and in timely isolation of infected patients with overlapping clinical symptoms. A recent study has shown that 5.8% of SARS-CoV-2 infected and 18.4% of non-SARS-CoV-2-infected patients had other concurrent pathogen infections. Failure to distinguish different pathogens may lead to unnecessary antimicrobial use, cross-infection of mis-grouped patients and further spreading of the infection. Therefore, in response to the current outbreak, singleplex testing is not optimal, especially considering the virus may become permanently and globally endemic. Simple, sensitive and multiplex detection of all respiratory pathogens is technically challenging. In response to the need for faster and better detection of multiple respiratory pathogens, GeneFirst has developed a prototype using its innovative proprietary technology - MPA (Multiplex Probe Amplification) - to simultaneously detect and differentiate SARS-CoV-2 as well as 30 other common respiratory bacteria and viruses. This assay will allow for accurate, cost-effective and comprehensive diagnoses during the current outbreak as well as future routine diagnosis. In this project, the consortium aims to analytically and clinically validate (CE-mark) this assay on two automated platforms for Point-of-Care and core pathology testing. This strategy provides maximum flexibility in screening and triage, allowing better and faster care, alleviating pressures on healthcare systems and improving patient recovery rates. GeneFirst aim to commercialise the assay for £8.50 (€9.00) per test.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores